Trial Profile
Myfortic Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Islet cell transplant rejection
- Focus Pharmacodynamics
- 01 Mar 2022 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
- 01 Mar 2022 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 15 Dec 2019 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.